Teva Seeks to Outbid Endo With $150 Million NuPathe Offer

Teva Pharmaceutical Industries Ltd. (TEVA) offered at least $150 million to acquire U.S. migraine treatment maker NuPathe Inc. (PATH), seeking to outbid a previous offer from Endo Health Solutions Inc. (ENDP)

Teva said it proposed to pay $3.65 a share, or $150 million, plus as much as $3.15 a share if sales goals are achieved related to the migraine drug Zecuity. Endo’s bid, announced Dec. 16, was for $105 million in cash plus as much as $3.15 per share in milestone payments.

Zecuity, approved in the U.S. last year, uses a battery-powered patch to deliver the treatment through the skin. Conshohocken, Pennsylvania-based NuPathe is also developing products for neurological diseases including Parkinson’s, schizophrenia and bipolar disorder.

NuPathe’s board hasn’t decided whether the Teva proposal is superior, NuPathe said today in a filing. Teva declined to comment on talks with NuPathe. Voice messages left with NuPathe’s investor relations representative and with a spokesman from Chadds Ford, Pennsylvania-based Endo weren’t immediately returned.

Teva’s American depositary receipts, each equal to one regular share of the Petach Tikva, Israel-based drugmaker, fell less than 1 percent to $41.05 at the close in New York. NuPathe gained 36 percent to $4.38.

To contact the reporter on this story: David Wainer in Tel Aviv at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.